Concomitant utilization of XANAX with solid CYP3A inhibitors incorporates a profound effect on the clearance of alprazolam, resulting in amplified concentrations of alprazolam and amplified risk of adverse reactions [see Scientific Pharmacology (12.3)]. Avoidance or administration Neonates born t